Prognostic relevance of integrated genetic profiling in adult T-cell acute lymphoblastic leukemia

Blood

Volumn 122, Issue 1, 2013, Pages 74-82

  Van Vlierberghe, Pieter ^a   Ambesi Impiombato, Alberto ^a   De Keersmaecker, Kim ^a,b,c   Hadler, Michael ^a   Paietta, Elisabeth ^d   Tallman, Martin S ^e   Rowe, Jacob M ^f,g   Forne, Carles ^h   Rue, Montserrat ^h   Ferrando, Adolfo A ^a  

^a NewYork Presbyterian Hospital   (United States)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^d MONTEFIORE MEDICAL CENTER   (United States)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^f TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^g SHAARE ZEDEK MEDICAL CENTER   (Israel)

^h UNIVERSITY OF LLEIDA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BCL 11 B PROTEIN; CD8 ANTIGEN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYCLIN DEPENDENT KINASE INHIBITOR 2B; DNA METHYLTRANSFERASE 3A; FBXW 7 PROTEIN; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; L SELECTIN; MICROSOMAL AMINOPEPTIDASE; NOTCH1 RECEPTOR; PROTEIN P53; TRANSCRIPTION FACTOR ETV6; TRANSCRIPTION FACTOR EZH2; TRANSCRIPTION FACTOR GATA 3; TRANSCRIPTION FACTOR RUNX1; UNCLASSIFIED DRUG; WT1 PROTEIN; MEMBRANE PROTEIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ALLELE; ANTIGEN EXPRESSION; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CHROMOSOME 17; CHROMOSOME DELETION; CHROMOSOME DELETION 17; GENE DOSAGE; GENE EXPRESSION PROFILING; GENE MUTATION; GENETIC ASSOCIATION; HETEROZYGOTE; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; MAJOR CLINICAL STUDY; ONCOGENE MYB; OVERALL SURVIVAL; PRIORITY JOURNAL; T CELL LEUKEMIA; T LYMPHOCYTE ACUTE LYMPHOBLASTIC LEUKEMIA; TUMOR SUPPRESSOR GENE; ADULT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETICS; GENOMICS; MALE; METABOLISM; MICROARRAY ANALYSIS; MORTALITY; PHASE 3 CLINICAL TRIAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR;

ADULT; FEMALE; GENE DOSAGE; GENE EXPRESSION REGULATION, LEUKEMIC; GENOMICS; HUMANS; IMMUNOPHENOTYPING; MALE; MEMBRANE PROTEINS; MICROARRAY ANALYSIS; PRECURSOR T-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; RISK FACTORS; TRANSCRIPTION, GENETIC;

EID: 84883720120     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-03-491092     Document Type: Article

References (54)

1. Ferrando AA, Neuberg DS, Staunton J, et al. Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell. 2002;1(1):75-87. (Pubitemid 41039178)
2. Hebert J, Cayuela JM, Berkeley J, Sigaux F. Candidate tumor-suppressor genes MTS1 (p16INK4A) and MTS2 (p15INK4B) display frequent homozygous deletions in primary cells from T- but not from B-cell lineage acute lymphoblastic leukemias. Blood. 1994;84(12):4038-4044.
3. Weng AP, Ferrando AA, Lee W, et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science. 2004;306(5694):269-271. (Pubitemid 39336870)
4. Van Vlierberghe P, Ferrando A. The molecular basis of T cell acute lymphoblastic leukemia. J Clin Invest.2012;122(10):3398-3406.
5. De Keersmaecker K, Atak ZK, Li N, et al. Exome sequencing identifies mutation in CNOT3 and ribosomal genes RPL5 and RPL10 in T-cell acute lymphoblastic leukemia. Nat Genet.2013;45(2):186-190.
6. Zhang J, Ding L, Holmfeldt L, et al. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature.2012;481(7380):157-163.
7. Homminga I, Pieters R, Langerak AW, et al. Integrated transcript and genome analyses reveal NKX2-1 and MEF2C as potential oncogenes in T cell acute lymphoblastic leukemia. Cancer Cell.2011;19(4):484-497.
8. Soulier J, Clappier E, Cayuela JM, et al. HOXA genes are included in genetic and biologic networks defining human acute T-cell leukemia (T-ALL). Blood. 2005;106(1):274-286. (Pubitemid 40967203)
9. Van Vlierberghe P, van Grotel M, Tchinda J, et al. The recurrent SET-NUP214 fusion as a new HOXA activation mechanism in pediatric T-cell acute lymphoblastic leukemia. Blood.2008;111(9):4668-4680.
10. Coustan-Smith E, Mullighan CG, Onciu M, et al. Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol.2009;10(2):147-156.
11. Van Vlierberghe P, Ambesi-Impiombato A, Perez-Garcia A, et al. ETV6 mutations in early immature human T cell leukemias. J Exp Med.2011;208(13):2571- 2579.
12. Gutierrez A, Dahlberg SE, Neuberg DS, et al. Absence of biallelic TCRgamma deletion predicts early treatment failure in pediatric T-cell acute lymphoblastic leukemia. J Clin Oncol.2010;28(24):3816-3823.
13. Graux C, Cools J, Melotte C, et al. Fusion of NUP214 to ABL1 on amplified episomes in T-cell acute lymphoblastic leukemia. Nat Genet. 2004;36(10):1084-1089. (Pubitemid 41184470)
14. Marks DI, Paietta EM, Moorman AV, et al. T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII/ECOG 2993). Blood.2009;114(25):5136-5145.
15. Wiernik PH, Paietta E, Goloubeva O, et al Eastern Cooperative Oncology Group. Phase II study of theophylline in chronic lymphocytic leukemia: a study of the Eastern Cooperative Oncology Group (E4998). Leukemia. 2004;18(10):1605-1610. (Pubitemid 39386337)
16. Gould J, Getz G, Monti S, Reich M, Mesirov JP. Comparative gene marker selection suite. Bioinformatics. 2006;22(15):1924-1925. (Pubitemid 44283041)
17. Van Vlierberghe P, Meijerink JP, Stam RW, van der Smissen W, van Wering ER, Beverloo HB, Pieters R. Activating FLT3 mutations in CD4+/CD8- pediatric T-cell acute lymphoblastic leukemias. Blood. 2005;106(13):4414-4415. (Pubitemid 41775958)
18. Ley TJ, Ding L, Walter MJ, et al. DNMT3A mutations in acute myeloid leukemia. N Engl J Med.2010;363(25):2424-2433.
19. Andersson AK, Miller DW, Lynch JA, et al. IDH1 and IDH2 mutations in pediatric acute leukemia. Leukemia.2011;25(10):1570-1577.
20. Zenatti PP, Ribeiro D, Li W, et al. Oncogenic IL7R gain-of-function mutations in childhood T-cell acute lymphoblastic leukemia. Nat Genet.2011;43(10):932-939.
21. Thompson BJ, Buonamici S, Sulis ML, et al. The SCFFBW7 ubiquitin ligase complex as a tumor suppressor in T cell leukemia. J Exp Med. 2007;204(8):1825-1835. (Pubitemid 47236320)
22. Van Vlierberghe P, Palomero T, Khiabanian H, et al. PHF6 mutations in T-cell acute lymphoblastic leukemia. Nat Genet.2010;42(4):338-342.
23. De Keersmaecker K, Real PJ, Gatta GD, et al. The TLX1 oncogene drives aneuploidy in T cell transformation. Nat Med.2010;16(11):1321-1327.
24. Tosello V, Mansour MR, Barnes K, et al. WT1 mutations in T-ALL. Blood.2009;114(5):1038-1045.
25. Ntziachristos P, Tsirigos A, Van Vlierberghe P, et al. Genetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia. Nat Med.2012;18(2):298-301.
26. Della Gatta G, Palomero T, Perez-Garcia A, et al. Reverse engineering of TLX oncogenic transcriptional networks identifies RUNX1 as tumor suppressor in T-ALL. Nat Med.2012;18(3):436-440.
27. Stirewalt DL, Kopecky KJ, Meshinchi S, Appelbaum FR, Slovak ML, Willman CL, Radich JP. FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia. Blood.2001;97(11):3589-3595.
28. Palomero T, Sulis ML, Cortina M, et al. Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia. Nat Med. 2007;13(10):1203-1210. (Pubitemid 47530629)
29. Tibshirani R. The lasso method for variable selection in the Cox model. Stat Med. 1997;16(4):385-395. (Pubitemid 27073009)
30. Verweij PJ, Van Houwelingen HC. Cross-validation in survival analysis. Stat Med. 1993;12(24):2305-2314. (Pubitemid 24007150)
31. Inukai T, Kiyokawa N, Campana D, et al. Clinical significance of early T-cell precursor acute lymphoblastic leukaemia: results of the Tokyo Children's Cancer Study Group Study L99-15. Br J Haematol.2012;156(3):358-365.
32. Bassan R, Hoelzer D. Modern therapy of acute lymphoblastic leukemia. J Clin Oncol.2011;29(5):532-543.
33. Hoelzer D, Gökbuget N, Ottmann O, et al. Acute lymphoblastic leukemia. Hematology (Am Soc Hematol Educ Program).2002;2002(1):162-192.
34. Yang YL, Hsiao CC, Chen HY, et al. Absence of biallelic TCRγ deletion predicts induction failure and poorer outcomes in childhood T-cell acute lymphoblastic leukemia. Pediatr Blood Cancer.2012;58(6):846-851.
35. Callens C, Baleydier F, Lengline E, et al. Clinical impact of NOTCH1 and/or FBXW7 mutations, FLASH deletion, and TCR status in pediatric T-cell lymphoblastic lymphoma. J Clin Oncol.2012;30(16):1966-1973.
36. Gutierrez A, Sanda T, Grebliunaite R, et al. High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia. Blood.2009;114(3):647-650.
37. Lahortiga I, De Keersmaecker K, Van Vlierberghe P, et al. Duplication of the MYB oncogene in T cell acute lymphoblastic leukemia. Nat Genet. 2007;39(5):593-595. (Pubitemid 46676109)
38. Graux C, Cools J, Michaux L, Vandenberghe P, Hagemeijer A. Cytogenetics and molecular genetics of T-cell acute lymphoblastic leukemia: from thymocyte to lymphoblast. Leukemia. 2006;20(9):1496-1510. (Pubitemid 44264091)
39. Diccianni MB, Yu J, Hsiao M, Mukherjee S, Shao LE, Yu AL. Clinical significance of p53 mutations in relapsed T-cell acute lymphoblastic leukemia. Blood. 1994;84(9):3105-3112. (Pubitemid 24328104)
40. Hof J, Krentz S, van Schewick C, et al. Mutations and deletions of the TP53 gene predict nonresponse to treatment and poor outcome in first relapse of childhood acute lymphoblastic leukemia. J Clin Oncol.2011;29(23):3185-3193.
41. Krieger D, Moericke A, Oschlies I, Zimmermann M, Schrappe M, Reiter A, Burkhardt B. Frequency and clinical relevance of DNA microsatellite alterations of the CDKN2A/B, ATM and p53 gene loci: a comparison between pediatric precursor T-cell lymphoblastic lymphoma and T-cell lymphoblastic leukemia. Haematologica.2010;95(1):158-162.
42. Breit S, Stanulla M, Flohr T, et al. Activating NOTCH1 mutations predict favorable early treatment response and long-term outcome in childhood precursor T-cell lymphoblastic leukemia. Blood. 2006;108(4):1151-1157. (Pubitemid 44232009)
43. Clappier E, Collette S, Grardel N, et al EORTC-CLG. NOTCH1 and FBXW7 mutations have a favorable impact on early response to treatment, but not on outcome, in children with T-cell acute lymphoblastic leukemia (T-ALL) treated on EORTC trials 58881 and 58951. Leukemia.2010;24(12):2023-2031.
44. Kox C, Zimmermann M, Stanulla M, et al. The favorable effect of activating NOTCH1 receptor mutations on long-term outcome in T-ALL patients treated on the ALL-BFM 2000 protocol can be separated from FBXW7 loss of function. Leukemia.2010;24(12):2005-2013.
45. Zuurbier L, Homminga I, Calvert V, et al. NOTCH1 and/or FBXW7 mutations predict for initial good prednisone response but not for improved outcome in pediatric T-cell acute lymphoblastic leukemia patients treated on DCOG or COALL protocols. Leukemia.2010;24(12):2014-2022.
46. Ben Abdelali R, Asnafi V, Leguay T, et al Group for Research on Adult Acute Lymphoblastic Leukemia. Pediatric-inspired intensified therapy of adult T-ALL reveals the favorable outcome of NOTCH1/FBXW7 mutations, but not of low ERG/BAALC expression: a GRAALL study. Blood.2011;118(19):5099-5107.
47. Mansour MR, Sulis ML, Duke V, et al. Prognostic implications of NOTCH1 and FBXW7 mutations in adults with T-cell acute lymphoblastic leukemia treated on the MRC UKALLXII/ECOG E2993 protocol. J Clin Oncol.2009;27(26):4352-4356.
48. Baldus CD, Thibaut J, Goekbuget N, et al. Prognostic implications of NOTCH1 and FBXW7 mutations in adult acute T-lymphoblastic leukemia. Haematologica.2009;94(10):1383-1390.
49. Asnafi V, Buzyn A, Le Noir S, et al. NOTCH1/FBXW7 mutation identifies a large subgroup with favorable outcome in adult T-cell acute lymphoblastic leukemia (T-ALL): a Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL) study. Blood.2009;113(17):3918-3924.
50. Bandapalli OR, Zimmermann M, Kox C, et al. NOTCH1 activation clinically antagonizes the unfavorable effect of PTEN inactivation in BFM-treated children with precursor T-cell acute lymphoblastic leukemia [published online ahead of print January 24, 2013]. Haematologica.
51. Fröhling S, Schlenk RF, Breitruck J, et al AML Study Group Ulm. Acute myeloid leukemia. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. Blood. 2002;100(13):4372-4380. (Pubitemid 35434129)
52. Ribeiro AF, Pratcorona M, Erpelinck-Verschueren C, et al. Mutant DNMT3A: a marker of poor prognosis in acute myeloid leukemia. Blood.2012;119(24):5824- 5831.
53. Patel JP, Gönen M, Figueroa ME, et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med.2012;366(12):1079-1089.
54. Grossmann V, Haferlach C, Weissmann S, et al. The molecular profile of adult T-cell acute lymphoblastic leukemia: mutations in RUNX1 and DNMT3A are associated with poor prognosis in T-ALL. Genes Chromosomes Cancer.2013;52(4): 410-422.